CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
靶向套细胞淋巴瘤免疫微环境：对当前与新兴治疗的启示
英文原题：Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies.
查看英文原题
Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
套细胞淋巴瘤（MCL）是非霍奇金淋巴瘤的一种亚型，在形态学和表型上具有异质性，历来预后较差。然而，近期对该病认识的进展带来了具有良好活性的靶向和免疫疗法。单克隆抗体、免疫调节剂和 CAR-T 细胞等免疫疗法显著改善了结局，目前已成为 MCL 标准治疗。本文介绍我们对 MCL 免疫微环境的当前认识，讨论现有免疫治疗方法，并重点介绍有望进一步改善 MCL 患者结局的新型免疫疗法和联合疗法。
展开英文摘要原文
Mantle cell lymphoma (MCL) is a morphologically and phenotypically heterogeneous subtype of non-Hodgkin lymphoma, and has historically been associated with poor outcomes.
However, recent advances in our understanding of this disease have yielded new targeted and immune-based therapies with promising activity. Immune-based therapies such as monoclonal antibodies, immunomodulators, and CAR T cells have significantly improved outcomes and are now standard of care in MCL.
In this review, we describe our current understanding of the immune microenvironment of MCL, discuss current immunotherapeutic approaches, and highlight promising novel immune-based therapies and combination therapies that may further improve outcomes for patients with MCL.
论文信息
- 作者
- Qualls D、Kumar A、Epstein-Peterson ZD
- 单位
- Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.United States
- 文献类型
- 综述 · 美国 NIH 资助研究 · 非美国政府资助研究
- 期刊
- Leukemia & lymphoma2022 Nov
- 原文标识
- PubMed 35704674 · DOI 10.1080/10428194.2022.2086244
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →